Crunch Time For Glenmark’s US Innovation Arm, Founding CEO To Exit

Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.

challenge
Crucial Year Ahead For Ichnos To Navigate • Source: Alamy

Significant changes appear to be underway at Glenmark Pharmaceuticals Limited’s fledgling innovation spin-out company in the US, Ichnos Sciences, Inc., with high-profile founding CEO Alessandro Riva now set to depart.

Riva, a former executive vice-president, Oncology Therapeutics, at Gilead Sciences, Inc., had taken up the top job at Ichnos...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip